Experimental proapoptotic peptide
An experimental peptide designed to destroy the blood vessels that feed fat tissue, causing fat cells to die off.
| Class / type | Experimental proapoptotic peptide |
|---|---|
| Category | Metabolic & Weight |
| Status (Jul 2026) | Research use only |
Targets prohibitin on the vasculature of white adipose tissue and triggers apoptosis of those blood vessels, cutting off the fat's blood supply so fat cells shrink and are reabsorbed.
Investigated in animal models for obesity; showed weight and fat loss in obese monkeys but has not been proven in humans.
Preclinical studies reported significant fat loss and improved insulin sensitivity in obese rhesus monkeys over about 28 days.
An early human trial was terminated over kidney toxicity (nephrotoxicity), and there is no established safe dose or completed human efficacy data.
Interest is driven by dramatic animal fat-loss results, but reported human sentiment is minimal given the lack of safe, legal access.
NOT FDA-approved: purely experimental with no approved indication, no completed human efficacy trial, and no legal pathway for human use as of 2026.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.